LONDON (Reuters) - Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets.






source Reuters: Business News http://ift.tt/1v94I0M